Skip to content
Hot eventDeveloping

a16z invests in Boltz as it raises $110M Series A

1 reports1 reporting sourcesUpdated 2 h ago

Start here

AI digest

Andreessen Horowitz (a16z) said it is investing in Boltz, a molecular design model startup that has closed a $110M Series A. a16z's Jorge Conde announced the investment; a16z had co-led Boltz's seed round last year, by which point the company's open-source models had reached every top 20 pharmaceutical company. Boltz's commercial models are already deployed at Pfizer, GSK, Takeda and BMS, and the company charges for model usage while scientists retain ownership of what they create. According to a16z, Boltz can also train exclusive versions of its models on a partner's proprietary data, giving pharma companies molecular intelligence shaped by their own research. Weekly molecular token consumption by customers has risen roughly 50-fold in the last four months, a16z said, following the launches of BoltzMol-1 and BoltzProt-1.

Generated from reports · updated 1 h ago

Report timeline

Follow the reports to see the event from different sides.

November 18
  1. a16z News
    a16z invests in Boltz as the startup closes a $110M Series A

    a16z's Jorge Conde announced the firm is investing in Boltz, which has raised a $110M Series A for its molecular design models. Boltz's open-source models had reached every top 20 pharmaceutical company by the time a16z co-led its seed round last year, and weekly molecular token consumption by customers has risen roughly 50-fold in the last four months following the launches of BoltzMol-1 and BoltzProt-1. Boltz's commercial models are already deployed at Pfizer, GSK, Takeda and BMS, and the company charges for model usage while scientists retain ownership of what they create.

Heat for this event

Not enough continuous observations yet to draw a trend.